Company Overview
Verrica Pharmaceuticals Inc. operates as a dermatology therapeutics company dedicated to the development and commercialization of medications designed to treat dermatologic diseases within the United States. This specialized focus places the company squarely within the broader Healthcare sector, specifically the Biotechnology industry, where it leverages scientific innovation to address specific medical needs. The firm currently employs 76 individuals and holds a market capitalization of $75.24M, generating total revenue of $35.58M over the trailing twelve months. These valuation and revenue figures indicate that Verrica Pharmaceuticals occupies a niche position in the market, reflecting the typical scale of a biotechnology entity that is likely prioritizing product pipeline advancement and market penetration over the massive revenue generation seen in mature pharmaceutical giants.
Financial Health
The company reported a revenue of $35.58M for the trailing twelve months, yet this generated a net income of $-17,886,000 and an EBITDA of $-11,454,000, revealing a cost structure where operating expenses significantly exceed total revenue. This substantial gap between positive revenue and negative net income highlights the high burn rate characteristic of early-stage or growth-phase biotechnology firms investing heavily in research, development, and commercialization efforts. While the company operates with negative net income, it maintains a cash balance of $30.15M, providing a buffer against its free cash flow of $-15,459,625, which indicates ongoing cash consumption from operations. The gross margin stands at 65.4%, suggesting that the core production of its drug-device combination retains a significant portion of revenue as gross profit before overheads. However, the operating margin of -136.4% and profit margin of -50.3% demonstrate that administrative and selling expenses are disproportionately high relative to sales, driving overall profitability into negative territory. Regarding leverage, total cash of $30.15M exceeds total debt of $1.63M, but the debt-to-equity ratio of 6.59 suggests a highly leveraged capital structure relative to shareholder equity. Despite the debt level, the current ratio of 2.59 indicates strong short-term liquidity, as current assets are more than twice the value of current liabilities. Furthermore, the return on equity is -240.4% and the return on assets is -14.7%, metrics that reveal that management is currently utilizing capital to generate losses rather than returns, a common trajectory for companies in the biotechnology sector awaiting product approvals or significant sales milestones.
Valuation Assessment
The trailing twelve-month P/E ratio is N/A due to the lack of net income, while the forward P/E is listed as -2.57, implying that the market expects earnings to remain negative or that valuation is being assessed on non-traditional metrics. The price-to-book ratio of 3.04 suggests that the market is pricing the company at a premium of roughly three times its net asset value, reflecting potential future value in its intellectual property or pipeline rather than current book value. Alternative valuation metrics such as the price-to-sales ratio of 2.11 and an EV/EBITDA of -4.08 provide context, indicating that the company is valued based on revenue multiples given the absence of positive earnings. In terms of trading range, the stock has a 52-week high of $9.82 and a 52-week low of $3.28; without a specific current price provided in the facts, the valuation is strictly bound by these historical boundaries which define investor sentiment over the last year. The beta of 1.46 indicates that the stock exhibits price volatility that is approximately 46% higher than the broader market, suggesting that price movements in Verrica Pharmaceuticals will likely be more pronounced than those of the general market index.
Growth & Income
Revenue growth for the trailing twelve months is recorded at an extraordinary 1380.2% year-over-year, while earnings growth is N/A due to the company's continued net losses. This disparity implies that the massive revenue expansion is not yet translating into profitability, a pattern often seen when revenue recognition accelerates due to new product launches or contract signings before the associated costs stabilize. As a non-dividend payer, Verrica Pharmaceuticals reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that the company does not distribute earnings to shareholders and instead reinvests all available capital into its operational and developmental activities. The overall growth and income profile is characterized by aggressive top-line expansion driven by a 1380.2% revenue increase, coupled with a complete reliance on external capital or cash reserves to fund operations given the absence of dividend income and negative earnings growth.